Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 263 | 65 | 180 |
| Samples | 233 | 53 | 165 |
| Peptides | 199 | 41 | 160 |
Function
HSPA5 · Heat shock protein family A (Hsp70) member 5
The protein encoded by this gene is a member of the heat shock protein 70 (HSP70) family. This protein localizes to the lumen of the endoplasmic reticulum (ER) where it operates as a typical HSP70 chaperone involved in the folding and assembly of proteins in the ER and is a master regulator of ER homeostasis. During cellular stress, as during viral infection or tumorogenesis, this protein interacts with the transmembrane stress sensor proteins PERK (protein kinase R-like endoplasmic reticulum kinase), IRE1 (inositol-requiring kinase 1), and ATF6 (activating transcription factor 6) where it acts as a repressor of the unfolded protein response (UPR) and also plays a role in cellular apoptosis and senescence. Elevated expression and atypical translocation of this protein to the cell surface has been reported in viral infections and some types of cancer cells. At the cell surface this protein may facilitate viral attachment and entry to host cells. This gene is a therapeutic target for the treatment of coronavirus diseases and chemoresistant cancers. [provided by RefSeq, Jul 2020].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000324460 | P11021 | 263 | 199 |
Gene Properties
Recurrent Mutations
All 199 amino-acid changes on canonical ENST00000324460 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in HSPA5 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in HSPA5 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 10/40 25% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Endometrial Carcinoma | 3/42 7% | 18/612 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Hodgkins Lymphoma | 2/16 12% | 0/122 0% |
| Biliary Tract Carcinoma | 0/54 0% | 14/950 1% |
| Bladder Carcinoma | 1/58 2% | 13/956 1% |
| Melanoma | 0/210 0% | 22/1899 1% |
| Colorectal Carcinoma | 6/143 4% | 20/3239 1% |
| Gastric Carcinoma | 0/74 0% | 11/1809 1% |
| Neuroendocrine Tumour | 2/154 1% | 2/577 0% |
| Ovarian Carcinoma | 1/109 1% | 5/998 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Other Solid Cancers | 2/94 2% | 6/1515 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 4/810 0% |
| Hepatocellular Carcinoma | 0/46 0% | 10/2210 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Mesothelioma | 0/62 0% | 1/165 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 4/1390 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Other Sarcomas | 2/69 3% | 1/699 0% |
| Esophageal Carcinoma | 2/23 9% | 1/769 0% |
| Head and Neck Carcinoma | 0/85 0% | 6/1574 0% |
| Prostate Carcinoma | 0/13 0% | 7/2105 0% |
| Breast Carcinoma | 2/144 1% | 8/3264 0% |
| Kidney Carcinoma | 1/85 1% | 4/1862 0% |
| B-Cell Non-Hodgkins Lymphoma | 4/88 5% | 2/2534 0% |
| Cervical Carcinoma | 1/35 3% | 0/422 0% |
Mutation Distribution
Where HSPA5 is mutated · all tissues, split by cell line vs tissue
How many mutations in HSPA5 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 263 mutations in HSPA5
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|